UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934Date of Report: September 22, 2014
(Date of earliest event reported)
Boston Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NH
(State or other jurisdiction
of incorporation) 000-54586
(Commission File Number) 27-0801073
(IRS Employer
Identification Number)
1750 Elm Street, Suite 103, Manchester
(Address of principal executive offices) 03101
(Zip Code)
603-935-9799
(Registrant's telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release of Boston Therapeutics, Inc. dated September 22, 2014
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 22, 2014
BOSTON THERAPEUTICS, INC.
By: /s/ anthony squeglia
anthony squeglia
chief financial officer